仑伐替尼胶囊 | China Drugs ListLenvatinib capsules | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
其他
- 商品名
- Lenvima
- 企业
- Eisai GmbH (欧盟上市许可持有人)Eisai GmbH (EU authorization holder)
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 肿瘤科Oncology
- 公开来源记录的适应症
- 欧盟：用于成人对放射性碘难治的进展性局部晚期或转移性分化型甲状腺癌；既往未接受全身治疗的晚期或不可切除肝细胞癌；或在铂类治疗后不适合根治性手术或放疗的晚期或复发性子宫内膜癌中，与帕博利珠单抗联合。EU: Adults with progressive locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine; advanced or unresectable hepatocellular carcinoma without prior systemic therapy; or, with pembrolizumab, advanced or recurrent endometrial cancer after platinum-based treatment when curative surgery or radiation is unsuitable.
- 适应症来源与口径
- EMA英文EPAR概述和产品详情 查阅于 2026-11-02. 部分境外适应症；不确立中国批准范围。English EMA EPAR overview and product details accessed 2026-11-02. Selected overseas indications; does not establish the Chinese approved scope.
- 说明书信息局限
- 已链接监管机构产品资料／批准证据；本次核查尚未核实完整的现行处方资料文件。Regulatory product information / approval evidence is linked; a complete current prescribing-information document has not been verified in this review.
- 中国可获得性状态
- 本次导入未独立核实中国批准、当地批准适应症及当前供应情况。Chinese approval, locally approved indications and current availability have not been independently verified in this import.
- 海外状态
- 请参阅所链接的境外监管机构或厂商证据。批准及适应症因司法辖区而异；尚未确认当前供应情况。See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
- 医保分类
- 尚未核实Not yet verified
- 医保版本
- 中国国家医保信息待核实Chinese national insurance review pending
- 医保核查说明
- 本次新增记录尚未确定报销资格；缺少信息不代表未被纳入。No reimbursement determination was made for this addition; missing information is not proof of exclusion.
来源
- https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima
- Lenvima——EMA药品概述和产品详情Lenvima — EMA medicine overview and product details
Regulatory medicine overview · English EMA EPAR overview and product details accessed 2026-11-02
已核查英文一手来源。此证据描述所引用的境外司法辖区情况，不能核实中国批准、适应症、报销或在售情况。English primary source reviewed. This evidence describes the cited overseas jurisdiction and does not verify Chinese approval, indications, reimbursement or market availability.
证据核查日期：